Type 2 Diabetes Trial, Recruiting NCT05888688 Sponsor: University of Leicester Condition: Type 2 Diabetes
Back to Type 2 Diabetes

Type 2 Diabetes Trial, Recruiting

NCT05888688
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

For people with heart failure (Stage A/B, with preserved pumping function):

  • People who have been formally diagnosed with heart failure where the heart's pumping function is preserved (pumping more than 50% of blood out with each beat)
  • People whose condition has been stable for at least 3 months, with no hospital admissions during that time
  • People aged 65 or older
  • People who are willing to sign a written consent form to take part in the study

For people with heart failure (Stage C/D, with either preserved or reduced pumping function):

  • People who have been formally diagnosed with heart failure where the heart either pumps well (over 50%) or pumps weakly (under 40%)
  • People whose condition has been stable for at least 3 months, with no hospital admissions during that time
  • People aged 65 or older
  • People who are willing to sign a written consent form to take part in the study

For healthy volunteers:

  • People aged 18 or older
  • People who are able to provide written consent to participate

For people with Type 2 diabetes (without symptoms):

  • People aged 18 to 75
  • People with a confirmed, stable Type 2 diabetes diagnosis, recorded by a doctor or confirmed through a specific blood sugar test or a blood marker called HbA1c at 6.5% or above

Who may not be able to join:

For people with heart failure:

  • People who have a medical reason why they cannot safely have an MRI scan
  • People who are unable to walk or complete a 6-minute walking test
  • People who have a nerve or muscle condition that could affect muscle assessment, such as motor neurone disease, multiple sclerosis, muscle disorders, or muscle inflammation
  • People who regularly or occasionally take steroid tablets by mouth
  • People who have an untreated overactive or underactive thyroid
  • People who have been hospitalised due to heart failure in the past 3 months

For healthy volunteers:

  • People who have had, or currently show, any signs of heart failure
  • People who have risk factors known to be associated with developing heart failure, such as high blood pressure, diabetes, or coronary artery disease

For people with Type 2 diabetes (without symptoms):

  • People who experience chest pain (angina) or significant breathlessness limiting daily activity
  • People who have significant artery disease, such as a history of heart attack, previous procedures to open blocked arteries, stroke, mini-stroke, or circulation problems in the limbs
  • People who have an irregular heart rhythm known as atrial fibrillation or flutter
  • People who have moderate to severe heart valve disease
  • People who have a history of heart failure or a condition affecting the heart muscle
  • People who have Type 1 diabetes
  • People whose blood test results suggest they may actually have a form of Type 1 diabetes that developed in adulthood
  • People with moderate to severe kidney disease (confirm with trial site for exact measurement details)
  • People who have a medical reason why they cannot safely have an MRI scan

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Gerry McCann, BSc, MB, ChB, MRCP, MD, University of Leicester (UoL)

Phone: 44 (0)116 204 4786

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University of Leicester
Registry
ClinicalTrials.gov
Start date
6 December 2023
Est. completion
1 September 2026

Where this trial is recruiting

🇬🇧 United Kingdom

Primary endpoints

Volumetric quadriceps skeletal muscle mass (cm^3)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov